6533b837fe1ef96bd12a2a3b
RESEARCH PRODUCT
C-reactive protein but not soluble CD40 ligand and homocysteine is associated to common atherosclerotic risk factors in a cohort of coronary artery disease patients.
Nicoletta VivonaGiulia BivonaDavide NotoAngelo Baldassare Cefalu'Angelo FallettaMarcello CiaccioMaurizio AvernaBruna Lo SassoBl SassoG Chiarellosubject
AdultMalemedicine.medical_specialtyHomocysteineClinical BiochemistryCD40 LigandEnzyme-Linked Immunosorbent AssayDiseaseCoronary Artery DiseaseCoronary artery diseaseAnginaCohort Studieschemistry.chemical_compoundRisk FactorsInternal medicinemedicineCD40Humansc-reactiveMyocardial infarctionHomocysteineFramingham Risk Scorebiologybusiness.industryVascular diseaseC-reactive proteinGeneral MedicineMiddle Agedmedicine.diseaseC-Reactive Proteinchemistrybiology.proteinCardiologyFemalebusinessdescription
Abstract Objectives One third to one half of the variation in vascular disease occurrence remains unexplained by traditional risk factors. Since atherosclerosis may, in part, be an inflammatory disease, circulating factors related to inflammation may be predictors of cardiovascular disease. The aim of this study was to evaluate the association between common atherosclerotic risk factors and markers of inflammation. Design and methods Serum levels of soluble CD40 (sCD40L), high-sensitive C-reactive protein (hs-CRP) and homocysteine (Hcy) were measured in 251 patients selected from a series of 438 subjects affected by previous myocardial infarction, angina or other cardiovascular diseases. Results sCD40L levels were lower in patients with previous myocardial infarction while no association was observed between sCD40L and Hcy levels and other risk factors. Only hs-CRP levels positively correlated with increased number of risk factors. Conclusion In a setting of patients affected with coronary artery disease no association between sCD40L and homocysteine levels and atherosclerotic risk factors was observed; only hs-CRP showed increased levels according to the number of risk factors. Future studies using larger cohorts will be needed to validate the clinical use of markers of inflammation in the prediction of cardiovascular events.
year | journal | country | edition | language |
---|---|---|---|---|
2009-11-01 |